Dow Jones
35 950,89 +520,47 (+1,47 %) Nasdaq
14 226,22 -32,27 (-0,23 %) Nikkei 225
33 475,37 -11,52 (-0,03 %) EUR/USD
1,0911 +0,0018 (+0,16 %) HANG SENG
16 925,85 -117,03 (-0,69 %) Bitcoin EUR
35 004,56 +190,60 (+0,55 %)
MRK Dec 2025 90.000 call
| Clôture précédente | 22,30 |
| Ouverture | 22,00 |
| Offre | 22,20 |
| Vente | 24,40 |
| Prix d’exercice | 90,00 |
| Date d’expiration | 2025-12-19 |
| Var. jour | 22,00 - 22,30 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 201 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
